Print Page  Close Window

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.50 (2.11%)
Data as of 10/17/17 4:00 p.m. ET

Latest News

Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria
Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.